Michael Steele

Company: Biocartis

Job title: Vice President, Business Development Pharma Partnering

Seminars:

Clinical need for rapid molecular testing in lung cancer patient management 3:00 pm

• Eighteen per cent (18%) of stage 4 NSCLC patients with non-squamous, NSCLC histology are at risk of rapid clinical deterioration and ¾ of these have a performance status 0, 1 or 2 at first MDT discussion. • Turnaround times for reporting somatic mutations in EGFR could be improved by using rapid, automated PCR-based testing…Read more

day: day 2 - pm -yellow